Thursday, 20 Sep 2018

You are here

Primary Sjögren's Syndrome Guideline from the British Society for Rheumatology

The British Society of Rheumatology (BSR) has been accredited by NICE to develop a guidance document for the management of primary Sjögren's Syndrome intended for rheumatologists, general physicians, general practitioners, specialist nurses and other specialists (e.g. ophthalmologists, dental practitioners and ENT specialists),

Primary SS (pSS) is a classic, immune-mediated, condition [1] typically presenting in women in their fifth or sixth decade, although up to 10% of cases occur in men. The prevalence in women in the UK is 0.1–0.4% [2]. Patients characteristically present with dryness of the eyes and mouth but systemic features are common and B-cell lymphoma affects 5–10% [3, 4].

Guidance was based on a literature reivew from 1990 to Jan 2016 and recommendations were only included where the mean strength of agreement (SOA) was ⩾7 and ⩾75% respondents scored ⩾7.

The guideline focus on several key areas. The following are key concepts taken from the guidance document.

Eyes

  • Humidification and avoidance of systemic medication that exacerbates dryness. LOE Ib/A; SOA 8.9 (97%).
  • Early referral to an ophthalmologist for review and consideration of insertion of punctual plugs or cauterization. LOE II/B; SOA 9.27 (100%).
  • Start with simple lubricating drops using the most cost-effective options (see Table 1 for preparations). LOE IV/D; SOA 9.3 (93.3%).
  • Avoid preservative-containing preparations. LOE I/A; SOA 9.21 (92.9%).
  • Refer patients with severe dry eye, not responding to conventional treatment, to specialist commissioned centres for consideration of serum eye drops. LOE IIb/B; SOA 9.5 (100%).
  • Low dose steroid-containing eye drops for short term use under ophthalmic supervision only. LOE Ib/A; SOA 9.64 (100%).
  • Avoid long term use of topical steroids. LOE Ib/A; SOA 9.64 (100%).
  • Ciclosporin eye drops or ointments under ophthalmic supervision for chronic inflammation. LOE Ib/A; SOA 9.38 (100%).
  • Use topical NSAIDs with caution under ophthalmic supervision only. LOE IIb/B; SOA 9.86 (100%).
  • A trial of pilocarpine 5 mg once daily increasing stepwise to 5 mg qds is recommended for patients with significant sicca symptoms. LOE IIb/B; SOA 9.08 (92.3%).

Mouth

  • Advise excellent oral hygiene, limit sugar intake and avoid food and drinks other than plain water between meals and from 1 h before bedtime and through the night. LOE IV/D; SOA 9.8 (100%).
  • Advise assessment by an oral medicine specialist and/or regular visits to a general dental practitioner. LOE IV/D; SOA 9.8 (100%).
  • Brush teeth at least twice daily (but not immediately after eating) including before bed using a pea sized amount of high fluoride toothpaste and use fluoride-containing oral gel on teeth twice daily. LOE I/A; SOA 9.8 (100%).
  • Chew xylitol-containing sugar-free gum. LOE IIb/B; SOA 9.67 (100%).
  • A trial of pilocarpine 5 mg once daily increasing stepwise to 5 mg qds if significant sicca symptoms. LOE IIb/B; SOA 9.77 (100%).

Management of salivary gland enlargement

  • Consider baseline US to assess for active inflammation, infection and stones. LOE IV/D; SOA 9.7 (100%).
  • If acute inflammation, in the absence of infection and stones, consider short course of oral prednisolone or intra-muscular depomedrone. LOE IV/D; SOA 9.01 (100%).

Systemic dryness

  • A trial of pilocarpine 5 mg once daily increasing stepwise to 5 mg qds if systemic dryness. LOE IV/D; SOA 9.08 (92.3%).
  • A non-hormonal vaginal moisturizer ± topical oestrogen if vaginal dryness. LOE I/A; SOA 9.8 (100%).

Treatment of systemic disease 

  • HCQ (6 mg/kg) for those with skin, joint disease or fatigue. LOE IIa/B; SOA 9.64 (100%).
  • Ciclosporin A may be helpful in patients with significant joint involvement. LOE III/C; SOA 8.58 (85.7%).
  • AZA may be considered in patients with systemic complications. LOE III/C; SOA 9.09 (100%).
  • MTX is useful for patients with an associated inflammatory arthritis. LOE IV/D SOA 9.54 (100%).
  • Mycophenolate may be considered in patients with systemic complications. LOE III/C; SOA 9.1 (100%).

Corticosteroids

  • Intermittent short courses of oral or intramuscular steroid for systemic flares and significant organ manifestations with or without additional immunosuppressive treatment. LOE III/C; SOA 9.2 (100%).
  • Low dose oral prednisolone for persistent constitutional symptoms in patients with inadequate response to other immunosuppresants. LOE IIb/B; SOA 8.92 (100%).
  • Rituximab for specialist use in patients with significant systemic manifestations refractory to other immunosuppresives and those with lymphoma, immune thrombocytopenia, vasculitic neuropathy or cryoglobulinaemia. LOE IIb/B; SOA 9.43 (100%).

Assessment and management of lymphoma

  • Review high risk patients regularly and warn patients to report firm, painless glandular swelling that does not settle. LOA IV/D; SOA 9.86 (100%).
  • Investigate suspicious lesions with local US, biopsy and CT chest, abdomen and pelvis for staging. LOA III/C; SOA9.77 (100%).
Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

An Association between GCA and IBD ?

A population based analysis from Israel suggests that giant cell arteritis (GCA) patients may be at increased risk for  inflammatory bowel diseases (IBD) mainly target.

This research was based on sporadic reports in the medical literature (http://bit.ly/2pnIPM0)

Breast Implant Study: More Worries or Not?

The Annals of Surgery reports on an anlaysis of FDA-mandated postmarket studies, including nearly 100,000 breast implant pprocedures, that showed silicone implants to be associated with higher rates of  Sjögren's syndrome, scleroderma, rheumatoid arthritis, stillbirth, and melanoma.

New Classification of Idiopathic Inflammatory Myopathies

Using an observational cohort analysis of patients in the French myositis network, researchers have proposed a new classification of idiopathic inflammatory myopathies (IIM) with four subgroups: dermatomyositis, inclusion body myositis, immune-mediated necrotizing myopathy, and antisynthetase syndrome.

Rsearchers set out to define a classification system for IIM based on phenotypic, biological, and immunologic criteria. 

Depression Increases Risk of Systemic Lupus Erythematosus

Twenty-year data from the Nurses’ Health Study (NHS) suggests that depression is associated with a 2-fold increased frequency of systemic lupus erythematosus (SLE) - the question is why?

Interferon Blocker Disappoints in SLE

Yet another setback has occurred in the efforts to develop new medications for treating systemic lupus erythematosus (SLE), as anifrolumab failed to meet the primary endpoint in a phase III trial, according to AstraZeneca and MedImmune.